Er Therapeutics Stock Analysis
| PNGM Stock | USD 0.0001 0.00 0.00% |
Er Therapeutics is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Er Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Er Therapeutics is worth, separate from its market price. There are two main types of Er Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Er Therapeutics stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Er Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. PNGM Stock trading window is adjusted to America/New York timezone.
PNGM |
PNGM Stock Analysis Notes
The company had not issued any dividends in recent years. Er Therapeutics had 3:1 split on the 13th of April 2009. Pengram Corporation, an exploration stage mining company, engages in the acquisition, exploration, and development of natural resource properties, primarily gold. Pengram Corporation was founded in 2006 and is based in Bellingham, Washington. Pengram Corp operates under Other Industrial Metals Mining classification in the United States and is traded on OTC Exchange. To find out more about Er Therapeutics contact Richard Donaldson at 360-255-3436 or learn more at https://pengramgold.com.Er Therapeutics Investment Alerts
| Er Therapeutics generated a negative expected return over the last 90 days | |
| Er Therapeutics has some characteristics of a very speculative penny stock | |
| Er Therapeutics currently holds 48.49 K in liabilities. Er Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Er Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (426.95 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Er Therapeutics currently holds about 650 in cash with (161.43 K) of positive cash flow from operations. | |
| Er Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Trevi Therapeutics Secures 50M Through Major Stock Offering, Backed by Healthcare Investment Giants - StockTitan |
PNGM Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 332.11 K.Management Efficiency
Er Therapeutics has return on total asset (ROA) of (0.9491) % which means that it has lost $0.9491 on every $100 spent on assets. This is way below average. Er Therapeutics' management efficiency ratios could be used to measure how well Er Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 10th of January 2025, Total Assets is likely to drop to about 283.4 K. In addition to that, Net Tangible Assets is likely to grow to about (96.1 K)At Er Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 10.396 | Return On Assets (0.95) |
Technical Drivers
In respect to fundamental indicators, the technical analysis model provides you with a way to check possible technical drivers of Er Therapeutics, as well as the relationship between them.Er Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Er Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Er Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Er Therapeutics Outstanding Bonds
Er Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Er Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PNGM bonds can be classified according to their maturity, which is the date when Er Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
About PNGM Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Er Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PNGM shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Er Therapeutics. By using and applying PNGM Stock analysis, traders can create a robust methodology for identifying PNGM entry and exit points for their positions.
Pengram Corporation, an exploration stage mining company, engages in the acquisition, exploration, and development of natural resource properties, primarily gold. Pengram Corporation was founded in 2006 and is based in Bellingham, Washington. Pengram Corp operates under Other Industrial Metals Mining classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Er Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.